Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadalafil sublingual - DMK Pharmaceuticals

Next Previous
Search
Drug Profile

Tadalafil sublingual - DMK Pharmaceuticals

Alternative Names: APC-8000

Latest Information Update: 13 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adamis Pharmaceuticals Corporation
  • Developer DMK Pharmaceuticals
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Gastrokinetics; Heart failure therapies; Indoles; Ischaemic heart disorder therapies; Pyridones; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 07 Sep 2023 Adamis Pharmaceuticals Corporation is now called DMK Pharmaceuticals
  • 30 Jun 2019 Discontinued - Preregistration for Erectile dysfunction in USA (Sublingual)
  • 26 Feb 2019 Adamis Pharmaceuticals plans to resubmit the NDA to the US FDA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top